Vendor, San Diego, CA
Blacksmith Medicines, Inc.
UEI ZCWKWSWHAJD6, CAGE 6XVV8
1 award and $829,012 obligated between September 11, 2026 and September 11, 2026, 100% under full and open competition, against 30.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $829,012 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93022C00060Definitive Contract, September 11, 2026, Full and Open Competition, 30 offers | National Institutes of Health NiaidNational Institutes of Health | FG-2101: a First-In-Class LPXC Inhibitor for the Treatment of MDR Gramnegative Urinary Tract Infections.NAICS 541715, PSC AN12 | $829,012 |
- Places of performance
- California
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 1 across 1 awards